Ascentage Pharma (AAPG) Director Amends Initial Holdings Report
ASCENTAGE PHARMA GROUP INTERNATIONAL
Subscribe to track AAPG
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Ascentage Pharma (AAPG) Director Amends Initial Holdings Report
Company: ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Form: 3/A (Amendment) | Filed: 2026-03-23 Significance: Low
Insider: Yu Debra Relationship: Director
Holdings Reported (Amendment): • Security: Options & RSUs • Total Underlying Shares: 45,930 • Details: 17,965 Options ($8.14 strike) + 27,965 RSUs
Key Insight: This is an administrative amendment to correct the number of share options and vesting schedules reported in the original Form 3 submission. No new market transaction occurred.
Market Context: Ascentage is a $16.35B biotech firm. These holdings represent ~0.01% of shares outstanding, indicating a standard compensation package for a director.
Comprehensive Analysis
SEC Filing Analysis: ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
Executive Summary
- Trading Significance: Low
- Key Takeaway: Director Debra Yu filed an amendment to correct the share counts and vesting details of her initial beneficial ownership report.
- Market Impact: Neutral; this is a clerical correction regarding compensation derivatives, not a market transaction.
Company Information
| Field | Value |
|---|---|
| Company | ASCENTAGE PHARMA GROUP INTERNATIONAL |
| Ticker Symbol | AAPG |
| CIK | 0002023311 |
| Industry | Pharmaceutical Preparations |
Insider Information
| Field | Value |
|---|---|
| Name | Yu Debra |
| CIK | 0001869480 |
| Title/Position | Director |
| Relationship | Director |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 3/A (Amendment) |
| Transaction Date | 2026-03-18 |
| Security Type | Options & Restricted Share Units |
| Shares Involved | 0 (Holdings Report) |
| Total Holdings Reported | 45,930 (Derivative Underlying) |
| Ownership Type | Direct |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Market Cap | $16.35 Billion |
| Shares Outstanding | 373,320,000 |
| Holdings % of Outstanding | ~0.012% |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: With a market cap of $16.35B, the reported holdings (valued roughly at $2M based on implied share price) are immaterial to the broader market float.
- Dilution Impact: The 45,930 underlying shares represent a negligible potential dilution of 0.012%.
- Transaction Significance: The filing is purely administrative (Form 3/A) to fix a reporting error in a previous submission (Footnote F4).
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: Amendments to Form 3s are procedural. This filing clarifies the director's compensation package (Options and RSUs) but does not involve buying or selling pressure.
Volume & Sentiment
- Expected Volume Impact: None.
- Sentiment Indicator: Neutral.
Additional Context
Transaction Notes
- Correction: Footnote F4 states, "The number of Share Options and/or vesting were inadvertently incorrectly reported in the original submission."
- Vesting: The options vest monthly starting Nov 2025; RSUs vest annually starting Nov 2026.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.